web analytics

Chemkart India Limited opens its IPO for subscription on July 7th 2025 and ends on July 9th 2025. It is a book-built offer with a total issue size of 32,29,200 equity shares, each with a face value of Rs.10. The price band ranges from Rs.236 - 238 for a lot size of 600, and is set to go public on July 14th 2025 on the Emerge platform of the Bombay Stock Exchange.

The company is a Mumbai-based company, engaged in the business of distributing specialized high-quality food and health ingredients to different manufacturers. It primarily deals with various nutritional, health, and sports supplement products. It offers a diverse range of captivated nutritional supplements and components like Amino Acids, Health Supplement, Herbal Extract, Nucleotide, Protein, Sports Nutrition, and Vitamin. The company has strong in-house processing and warehousing capabilities along with a dynamic team of experienced professionals. It has major geographical presence in Gujarat, Maharashtra, and New Delhi, and also operates considerably in the International market. The company aims to leverage its market skills and improve its product innovation and design, and further diversify its portfolio.

Table of Contents
Details Of Chemkart India Limited IPO
Objectives of Chemkart India Limited IPO
Financial Performance of Chemkart India Limited
Industry Outlook
Strengths and Risks of Chemkart India Limited
Strength:
IPO Subscription Details
Frequently Asked Questions: Chemkart India Limited

Details Of Chemkart India Limited IPO

chemkart ipo review
  • Fresh Issue Size: It provides a fresh issue size of 26,00,000 equity shares with a face value of Rs.10 
  • Offer for Sale: It provides an offer for sale of 62,29,200 equity shares with a face value of Rs.10
  • Price Range: The bid price for each equity share ranges from Rs.236-248 per share.
  • Issue Type: The IPO is a Book-built offer.
  • Lot size: It provides a lot size of 600. 
  • Subscription date: The issue period begins on July 7th 2025 and ends on July 9th 2025.
  • Listing Date: The IPO is going to be listed on July 14th 2025.
  • Stock Exchange: The IPO is going to be listed on BSE (SME).

    • Objectives of Chemkart India Limited IPO

    With the help of this IPO, the company proposes to utilize the net proceeds to finance its wholly-owned subsidiary (WOS) company, Easy Raw Materials Private Limited, repay its borrowings, and for general corporate purposes.

     Also Learn: What is an IPO?

    Financial Performance of Chemkart India Limited

    The table below (in lakhs) shows the restated Financial Information of the company over the last 3 fiscal years.

    Particulars  

    31.03.2025

    31.03.2024

    31.03.2023

    Share Capital

    949.90

    135.70


    135.70

    Total Net Worth

    5,328.57

    2,901.47

    1,449.67


    Revenue from operations

    20,545.63


    13,282.77


    13,168.62


    Profit After Tax

    2,425.75

    1,451.82

    766.02

    Industry Outlook

    The Global nutraceutical market that blends food, pharmaceuticals, and biotechnology is currently valued at around USD 400 billion. This sector is a recognized sector in India and is still growing, due to the rich heritage of Ayurveda and a unique ecosystem, which contributes around 2% to the global market.  


    The Government of India has constituted a Nutraceutical Sector Task Force to address challenges and concerns faced by the nutraceutical sector in India.


    India is a domestic-driven economy, and with a rising population, there has been a surge in demand for healthy supplements and diets due to the change in lifestyle. The Indian manufacturing sector is one of the most prominent sectors of the Indian economy, and this sector has the potential to reach USD 1 trillion by 2025-26. 

    The government is also constantly improving this sector with strategic initiatives like the Harmonized System of Nomenclature codes for streamlined trade, PLI Scheme, Nutraceutical Industry Panel, etc., along with infrastructure support and many nutraceutical incubation hubs.


    With a thriving startup ecosystem and a growing number of successful nutraceutical companies, India's nutraceutical sector is set for unprecedented growth and aims to position itself as a global leader in nutraceuticals.

    Strengths and Risks of Chemkart India Limited

    Strength:

  • The company deals with various nutritional, healths, and sports supplements products that are used to make healthy food products and supplements. It distributes its products to many B2B manufacturing companies that manufacture finished supplements.
  • It offers products across mainly seven product categories, i.e., Amino Acids, Health Supplement, Herbal Extract, Nucleotide, Protein, Sports Nutrition, and Vitamin.
  • The company has in-house processing and warehousing capabilities backed by the latest technology and a diverse team of experienced professionals. 
  • The company has shown healthy financial growth over the last three fiscal years, increasing its profit after tax from Rs.766.02 lakhs in 31.03.2023 to Rs.2,425.75 lakhs as of 31.03.2025.
    • Weakness;
  • The company is largely dependent on the timely supply of its products from a few of its suppliers and has not entered into any long-term supply contracts; any disruption in the supply chain may adversely affect the company's operations and financial conditions.
  • The company sources the majority of its products from China, and any adverse development in this region may have an adverse impact on the company's operations and financial conditions.
  • The company has been in the business since 2020 and has a limited working history in trading nutraceutical products and health supplements. With limited experience, the company may encounter many challenges that may have an adverse impact on the company's operations and financial conditions.
  • The company derives major revenue from the states of Gujarat, Maharashtra, and New Delhi, and a minor portion from the International market. Any adverse developments in these regions may have an adverse impact on the company's operations and financial conditions.
  • The company has experienced negative cash flow in the past and may experience the same in the future.

    • IPO Subscription Details

    The IPO offers a fresh issue size of 26,00,000 equity shares and an offer for sale of 6,29,200 equity shares, each with a face value of Rs.10, respectively. The bid price ranges from Rs.236-248 per share for a lot size of 600. The issue period begins from July 7th 2025 and ends on July 9th 2025 and is scheduled to go public on July 14th 2025 on the SME platform of BSE.

    Expert Recommendations

    The nutraceutical sector in India is a growing market. With the rapid growth of manufacturing, import and export, and the constant support of the Government, backed by ancient Ayurvedic practices, this sector is poised for unprecedented growth in India.

    The company has a diverse product portfolio and has shown remarkable financial growth since its inception in 2020, but the company is also subject to many risks, as outlined in the RHP draft, and investors should carefully review the risks given in the document before investing.

    Key Takeaways

     It has shown remarkable profits since its inception in 2020, but is also subject to many risks, which the investor should outline before investing.

    Frequently Asked Questions: Chemkart India Limited

    1. When is the Chemkart India Limited IPO being listed?

    The IPO is set to go public on July 14th 2025.

    2. Is the Chemkart India Limited IPO fairly priced?

    The Weighted Average EPS is 19.21, and the P/E ratio for the higher price band is 12.28 and 12.90 for the lower price band. The bid price ranges from Rs.236-248 per share.

    3. Where else can we get more information about the Chemkart India Limited IPO?

    You can get more information about the IPO on the BSE website.

    1. https://www.ibef.org/news/nutraceuticals-market-may-grow-to-us10-bn-by-2022

    2. https://chemkart.com/


    Also Learn About: Indogulf Cropsciences Limited IPO